Literature DB >> 32991858

Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer.

Muzna Hussain1, Yuan Hou2, Chris Watson3, Rohit Moudgil4, Chirag Shah5, Jame Abraham6, G Thomas Budd6, W H Wilson Tang4, J Emanuel Finet4, Karen James4, Jerry D Estep4, Bo Xu4, Bo Hu7, Paul Cremer4, Christine Jellis4, Richard A Grimm4, Neil Greenberg4, Zoran B Popovic4, Leslie Cho4, Milind Y Desai4, Steven E Nissen4, Samir R Kapadia4, Lars G Svensson8, Brian P Griffin4, Feixiong Cheng9, Patrick Collier10.   

Abstract

To evaluate the temporal relations of cardiovascular disease in oncology patients referred to cardio-oncology and describe the impact of cardiovascular disease and cardiovascular risk factors on outcomes. All adult oncology patients referred to the cardio-oncology service at the Cleveland Clinic from January 2011 to June 2018 were included in the study. Comprehensive clinical information were collected. The impact on survival of temporal trends of cardiovascular disease in oncology patients were assessed with a Cox proportional hazards model and time-varying covariate adjustment for confounders. In total, 6,754 patients were included in the study (median age, 57 years; [interquartile range, 47 to 65 years]; 3,898 women [58%]; oncology history [60% - breast cancer, lymphoma, and leukemia]). Mortality and diagnosis of clinical cardiac disease peaked around the time of chemotherapy. 2,293 patients (34%) were diagnosed with a new cardiovascular risk factor after chemotherapy, over half of which were identified in the first year after cancer diagnosis. Patients with preexisting and post-chemotherapy cardiovascular disease had significantly worse outcomes than patients that did not develop any cardiovascular disease (p < 0.0001). The highest 1-year hazard ratios (HR) of post-chemotherapy cardiovascular disease were significantly associated with male (HR 1.81; 95% confidence interval 1.55 to 2.11; p < 0.001] and diabetes [HR 1.51; 95% confidence interval 1.26 to 1.81; p < 0.001]. In conclusion, patients referred to cardio-oncology, first diagnosis of cardiac events peaked around the time of chemotherapy. Those with preexisting or post-chemotherapy cardiovascular disease had worse survival. In addition to a high rate of cardiovascular risk factors at baseline, risk factor profile worsened over course of follow-up.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32991858      PMCID: PMC7704696          DOI: 10.1016/j.amjcard.2020.09.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Acute and chronic remote ischemic conditioning attenuate septic cardiomyopathy, improve cardiac output, protect systemic organs, and improve mortality in a lipopolysaccharide-induced sepsis model.

Authors:  Takashi Honda; Quan He; Fangfei Wang; Andrew N Redington
Journal:  Basic Res Cardiol       Date:  2019-03-05       Impact factor: 17.165

2.  Organisation & models of cardio-oncology clinics.

Authors:  Dorothy M Gujral; Charlotte Manisty; Guy Lloyd; Sanjeev Bhattacharyya
Journal:  Int J Cardiol       Date:  2016-04-06       Impact factor: 4.164

3.  Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Authors:  Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

4.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

5.  Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

Authors:  Palma Fedele; Laura Orlando; Paola Schiavone; Mariangela Ciccarese; Rosa Chiara Forcignanò; Nicola Calvani; Antonella Marino; Angelo Nacci; Francesco Sponziello; Enrica Mazzoni; Pietro Rizzo; Vito Lorusso; Saverio Cinieri
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

6.  Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.

Authors:  Jihyoun Lee; Ho Hur; Jong Won Lee; Hyun Jo Youn; Kyungdo Han; Nam Won Kim; So-Youn Jung; Zisun Kim; Ku Sang Kim; Min Hyuk Lee; Se-Hwan Han; Sung Hoo Jung; Il Yong Chung
Journal:  Cancer       Date:  2019-08-27       Impact factor: 6.860

Review 7.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

Review 8.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

9.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

10.  Oncocardiology-Past, Present, and Future: A Review.

Authors:  Edward T H Yeh; Hui-Ming Chang
Journal:  JAMA Cardiol       Date:  2016-12-01       Impact factor: 14.676

View more
  2 in total

1.  A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors.

Authors:  Jessica Castrillon Lal; Sherry-Ann Brown; Patrick Collier; Feixiong Cheng
Journal:  Cardiooncology       Date:  2021-05-28

2.  Impact of timing of atrial fibrillation, CHA2DS2-VASc score and cancer therapeutics on mortality in oncology patients.

Authors:  Muzna Hussain; Rabel Misbah; Eoin Donnellan; Saqer Alkharabsheh; Yuan Hou; Feixiong Cheng; Michael Crookshanks; Chris J Watson; Andrew J Toth; Penny Houghtaling; Rohit Moudgil; G Thomas Budd; W H Wilson Tang; Deborah H Kwon; Wael Jaber; Brian Griffin; Mohamad Kanj; Patrick Collier
Journal:  Open Heart       Date:  2020-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.